The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
A rush of fresh blood greeted the introduction on April 30 of new rules by the Hong Kong stock exchange that will enhance its competitiveness and entice biotech and innovative pharma firms in particular.
The new rules agreed on by the Hong Kong Exchanges and Clearing (HKEX) and Securities and Futures Commission (SFC) will usher in a new era of listing reforms, while also
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
